JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Akciju saraksts・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Slēgts

31.94 -2.44

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.74

Max

32.75

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 331M
Pārdošana	203M 3.2B
P/E Sektora vidējais	23.923 60.328
Dividenžu ienesīgums	2.29
Peļņas marža	10.368
Darbinieki	16,988
EBITDA	133M 856M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+6.9% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.29% 2.24%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-578M 15B
Iepriekšējā atvēršanas cena	34.38
Iepriekšējā slēgšanas cena	31.94

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

26.64 / 28.37 Atbalsts un pretestība

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 23. apr. 23:47 UTC

Tirgus saruna

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026. g. 23. apr. 23:13 UTC

Iegādes, apvienošanās, pārņemšana

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026. g. 23. apr. 22:33 UTC

Peļņas

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Executed Offtake Agreement With Ronbay

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026. g. 23. apr. 22:16 UTC

Peļņas

PLS Commences Commissioning of Midstream Demonstration Plant

2026. g. 23. apr. 22:15 UTC

Peļņas

PLS Group Reaffirms FY26 Guidance for All Metrics

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026. g. 23. apr. 22:13 UTC

Peļņas

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:11 UTC

Peļņas

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026. g. 23. apr. 22:10 UTC

Peļņas

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026. g. 23. apr. 22:09 UTC

Peļņas

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026. g. 23. apr. 22:08 UTC

Peļņas

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026. g. 23. apr. 22:04 UTC

Peļņas

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026. g. 23. apr. 21:56 UTC

Tirgus saruna

Peļņas

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 23. apr. 21:27 UTC

Peļņas

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026. g. 23. apr. 21:25 UTC

Peļņas

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026. g. 23. apr. 21:24 UTC

Peļņas

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026. g. 23. apr. 21:24 UTC

Peļņas

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

6.9% augšup

Prognoze 12 mēnešiem

Vidējais 35 USD 6.9%

Augstākais 35 USD

Zemākais 35 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.